Valdecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is classified as a nonsteroidal anti-inflammatory drug (NSAID). Valdecoxib is used for its anti-inflammatory, analgesic, and antipyretic activities in the management of osteoarthritis (OA) and for the treatment of dysmenorrhea or acute pain.
Both COX-1 and COX-2 catalyze the conversion of arachidonic acid to prostaglandin (PG) H2, the precursor of PGs and thromboxane. Valdecoxib selectively inhibits the cyclooxygenase-2 (COX-2) enzyme, important for the mediation of inflammation and pain. Unlike non-selective NSAIDs, valdecoxib does not inhibit platelet aggregation.
ORAL Osteoarthritis; Rheumatoid arthritis: Adult: 10 mg once daily. Dysmenorrhoea: Adult: 20 mg bid.
Abacavir Valdecoxib may decrease the excretion rate of Abacavir which could result in a higher serum level.
Abametapir The serum concentration of Valdecoxib can be increased when it is combined with Abametapir.
Abatacept The metabolism of Valdecoxib can be increased when combined with Abatacept.
Abciximab The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Abciximab.
Abrocitinib The metabolism of Abrocitinib can be decreased when combined with Valdecoxib.
Hypersensitivity to sulfonamides, NSAIDs & other COX-2 inhibitors; asthma, urticaria; severe hepatic impairment; pregnancy (third trimester); lactation. Active GI bleed or ulceration, severe CHF, inflammatory bowel disease. Mild to moderate hepatic impairment; history of ulcer disease or GI bleeding; dehydration, hypertension, history of heart failure, left ventricular dysfunction, preexisting oedema. Monitor Hb or haematocrit values for signs & symptoms of anaemia.
Hypertension, back pain. myalgia, peripheral oedema, influenza-like symptoms, dizziness, headache, abdominal fullness, abdominal pain, diarrhoea, dyspepsia, flatulence, nausea, myalgia, sinusitis. Toxic epidermal necrolysis, exfoliative dermatitis.
Valdecoxib has been assigned to a pregnancy category C by the FDA. Animal studies have revealed evidence of teratogenicity. Data from human pregnancy studies are not available. Valdecoxib should only be given during pregnancy when benefit outweighs risk. There are no data on the excretion of valdecoxib into human milk. Valdecoxib and its active metabolite are excreted in the milk of lactating rats. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue valdecoxib, taking into account the importance of the drug to the mother.
Symptoms following acute NSAID overdoses are usually limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which are generally reversible with supportive care. Gastrointestinal bleeding can occur. Hypertension, acute renal failure, respiratory depression and coma may occur, but are rare.
Store in a cool and dry place, away from light Keep out of the reach of children.
.png&w=384&q=75)